Filter articles using the following links

GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the 45th annual meeting of NANOS

9th EURETINA Winter Meeting, Prague, Czech Republic

GenSight Biologics announces publication of positive safety data from Phase I/II trial of GS010 in the JAMA Ophthalmology

GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)

ARVO Annual Meeting, Vancouver, BC, Canada

GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

45th NANOS Annual Meeting, Las Vegas, Nevada, US

World Orphan Drug Congress Europe, Barcelona, Spain

GenSight Biologics enrolls first subject in first-in-man PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)